Latest news with #TAVR
Globe and Mail
a day ago
- Business
- Globe and Mail
Robust TMTT Growth to Drive Edwards Lifesciences' Q2 Earnings
Edwards Lifesciences Corp. EW is scheduled to report second-quarter 2025 results on July 24, after market close. In the last reported quarter, the company's adjusted earnings per share of 64 cents beat the Zacks Consensus Estimate by 6.67%. Its earnings beat estimates in two of the trailing four quarters and matched on the other two occasions, the average surprise being 3.49%. Q2 Estimates The Zacks Consensus Estimate for revenues is pegged at $1.49 billion, suggesting an 8.9% decline from the year-ago reported figure. The Zacks Consensus Estimate for net earnings of 62 cents per share indicates an 11.4% decline from the year-ago reported figure. Estimate Revision Trend Ahead of Edwards' Q2 Earnings Estimates for earnings have remained unchanged at 62 cents per share in the past 60 days. Here's a brief overview of the company's progress ahead of this announcement. Factors at Play In the second quarter of 2025, the Transcatheter Aortic Valve Replacement ('TAVR') arm is likely to have delivered a strong performance in the United States, thanks to its market-leading SAPIEN 3 Ultra RESILIA platform. The continued expansion of SAPIEN3 Ultra RESILIA in Europe is expected to have supported the international performance. The platform has demonstrated remarkable patient outcomes, and the momentum is expected to have continued with more centers adopting it. Although we expect the company to have endured a weak procedure growth environment and competitive pressure in Japan, it remained dedicated to addressing significant undertreatment of aortic stenosis among the country's substantial elderly population. On its previous earnings call, Edwards stated that it experienced a few instances of regional variability despite holding a strong competitive position and stable global pricing. The trend is likely to have continued in the second quarter, restricting the segment's full potential. Our model assumes TAVR sales to be $1.09 billion, implying a 5.2% year-over-year increase. In the Transcatheter Mitral and Tricuspid Therapies ('TMTT') segment, strength in the portfolio of repair and replacement technologies for both Mitral and Tricuspid valves is likely to have supported Edwards' performance in second-quarter 2025. The PASCAL repair system is expected to have gained traction in the United States, Europe and globally, thanks to its differentiated features, leading to increased adoption of the technology at both existing and new centers. Additionally, the commercial launch of the EVOQUE tricuspid replacement system might have continued to progress in the United States and Europe. As of March, it gained Medicare coverage under the finalized NCD for transcatheter tricuspid valve replacement, expanding access. Edwards Lifesciences Corporation Price and EPS Surprise Edwards Lifesciences Corporation price-eps-surprise | Edwards Lifesciences Corporation Quote Edwards has raised its 2025 sales guidance for this segment to $530-$550 million (earlier $500 million), and we expect the company to have progressed meaningfully in the to-be-reported quarter. Our model estimates the TMTT business to report revenues of $130.4 million, implying a 57.1% improvement from the year-ago period's level. Lastly, Edwards' Surgical Structural Heart might have delivered a strong performance in the to-be-reported quarter, driven by global adoption of its premium RESILIA portfolio, including MITRIS, INSPIRIS and KONECT. The company likely saw positive procedural growth globally for the many patients best treated surgically, including complex and concomitant procedures. Furthermore, MITRIS' launch in China with positive surgeon feedback might have contributed to the second-quarter top line. Our model estimates the segment's revenues to be $263.1 million, suggesting a modest 6.2% rise from the year-ago quarter's reported figure. Earnings Whispers for Edwards Per our proven model, stocks with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold), along with a positive Earnings ESP, have a higher chance of beating estimates, which is not the case here, as you can see below: Earnings ESP: Edwards has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter. Zacks Rank: The company currently carries a Zacks Rank #2. You can see the complete list of today's Zacks #1 Rank stocks here. Top MedTech Picks Here are some medical stocks worth considering, as these have the right combination of elements to post an earnings beat this reporting cycle: CVS Health CVS has an Earnings ESP of +2.06% and a Zacks Rank #1 at present. The company is slated to release second-quarter 2025 results on July 31. You can see the complete list of today's Zacks #1 Rank stocks here. CVS' earnings surpassed estimates in each of the trailing four quarters, the average surprise being 18.08%. The Zacks Consensus Estimate for second-quarter EPS implies a year-over-year decline of 19.7%. Cencora COR has an Earnings ESP of +1.49% and a Zacks Rank #2 at present. The company is slated to release third-quarter fiscal 2025 results on Aug. 6. The company's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 6.00%. The Zacks Consensus Estimate for fiscal third-quarter EPS implies a year-over-year increase of 13.2%. Cardinal Health CAH has an Earnings ESP of +0.68% and a Zacks Rank #2 at present. The company is expected to release fiscal fourth-quarter 2025 results on Aug. 12. CAH's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 10.30%. The Zacks Consensus Estimate for fiscal fourth-quarter EPS suggests a year-over-year improvement of 1.3%. Zacks' Research Chief Names "Stock Most Likely to Double" Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest. This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%. Free: See Our Top Stock And 4 Runners Up Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Cardinal Health, Inc. (CAH): Free Stock Analysis Report Edwards Lifesciences Corporation (EW): Free Stock Analysis Report CVS Health Corporation (CVS): Free Stock Analysis Report
News18
11-06-2025
- Health
- News18
Beyond Blockages: Structural Heart Disease and the Rise of Minimally Invasive Solutions
Last Updated: A common example of structural heart disease is aortic valve stenosis, especially in patients over 60 years old. Heart disease is often associated with blocked arteries and heart attacks, but there's another lesser-known category of heart conditions that demands attention: structural heart disease. While coronary artery disease is defined by the narrowing or blockage of arteries that nourish the heart muscle, structural heart disease refers to abnormalities or defects in the heart's valves, walls, muscles, or chambers. These can be congenital—present from birth—or acquired over time due to aging, infections such as rheumatic fever, or degenerative changes. A common example of structural heart disease is aortic valve stenosis, especially in patients over 60 years old. This occurs when calcium deposits restrict and stiffen the aortic valve, making it harder for the heart to pump blood efficiently. Another congenital condition is the bicuspid aortic valve, where the valve has only two cusps instead of the usual three, leading to accelerated wear and valve failure, often in younger adults. Dr. Yugal Mishra, Chief of Clinical Services, Chairman of the Manipal Institute of Cardiac Sciences, and Chief Cardiovascular Surgeon at Manipal Hospital, Dwarka, New Delhi, shares everything you need to know: New symptoms of structural heart disease can include difficulty breathing, fatigue during everyday activities, chest discomfort, irregular heartbeats, or swelling in the limbs or abdomen. These may signal that the heart's valves or chambers are not functioning properly and require immediate medical attention. Surgical options such as valve repair or replacement remain effective, particularly in younger patients or those with minimal comorbidities. However, less invasive options have revolutionized care for older patients or those with additional kidney or lung complications. One such procedure is TAVR (Transcatheter Aortic Valve Replacement), also known as TAVI. In this approach, a prosthetic valve is inserted via catheter through an artery, avoiding the need for open-heart surgery. This minimally invasive method is particularly beneficial for patients with severely compromised health, offering restored heart function, faster recovery, and improved quality of life. Advanced therapies like TAVR offer renewed hope for living a healthier, more fulfilling life. If you or a loved one is experiencing recurring cardiac symptoms, it is advisable to consult a cardiologist. Early detection and timely intervention can make all the difference. As highlighted by the World Health Organization, cardiovascular disease (CVD)—including heart attacks and strokes—remains the leading cause of death worldwide. Alarmingly, many of these deaths are premature, especially among individuals under 70. Aortic stenosis (AS) is a prime example of a condition that can progress silently until it becomes critical. To further improve outcomes, the SMART trial evaluated various valve types used in TAVR procedures, enhancing treatment protocols, safety, and long-term success rates. For India to meet the growing burden of heart disease, a multi-faceted healthcare approach—combining early diagnostics and innovative treatments like TAVI—is essential to transform cardiac care and improve patient outcomes. News lifestyle » health-and-fitness Beyond Blockages: Structural Heart Disease and the Rise of Minimally Invasive Solutions
Business Journals
10-06-2025
- Health
- Business Journals
Aurora St. Luke's Medical Center celebrates its 5,000th TAVR procedure
Aurora St. Luke's Medical Center and its team of world-renowned heart experts recently reached a historic milestone at the forefront of cardiac care. In May, Aurora St. Luke's completed its 5,000th transcatheter aortic valve replacement (TAVR), ranking fourth among all TAVR implanting sites in the United States. TAVR is a less invasive life-saving procedure for patients with aortic valve disease. According to the U.S. Centers for Disease Control and Prevention, more than 5 million Americans are diagnosed with valvular heart disease each year. Left untreated or improperly managed, valve disease makes it more difficult for the heart to pump blood and can eventually lead to heart failure. This condition often develops as a result of calcium buildup as a person ages. Symptoms of valve disease can include chest pain, rapid heartbeat, shortness of breath and lightheadedness. Developed as an alternative to open heart surgery, TAVR is done through a small incision in either the groin or chest and guide a catheter through blood vessels until they reach the damaged aortic valve. A new valve is inserted into the diseased valve. Once in place, the replacement valve expands to its full size and takes over the diseased valve's job of regulating blood flow. Compared to open heart surgery, TAVR carries a lower risk of complications and offers a much faster recovery time. Patients who undergo TAVR are released from the hospital within one to three days and can typically resume normal activity two weeks after the procedure. 'I'm proud of our innovative, highly specialized cardiologists who deliver excellent care, time and time again,' said Jennifer Schomburg, president of Aurora St. Luke's Medical Center and Southeast Wisconsin Area. 'From the first TAVR procedure to the 5,000th, our team has leveraged their knowledge and expertise to help patients regain their heart's function, their energy and the lives they love.' 'We've continued to grow and develop the TAVR program for more than 15 years,' said Dr. Tanvir Bajwa, director of interventional cardiology and co-director of the valve clinic at Aurora St. Luke's. 'While we're honored to mark this tremendous milestone, we're eager to find more ways to improve lives and restore hearts of those in our community.' Aurora St. Luke's was heavily involved in leading the clinical trials that led to TAVR's FDA approval. Today, the minimally invasive procedure is performed throughout the world, with Aurora St. Luke's operating the largest and most experienced TAVR program in Wisconsin. The heart of Aurora Health Care's cardiovascular program, Aurora St. Luke's is consistently ranked among the best in the country by U.S. News & World Report. Home to groundbreaking clinical trials, cardiovascular research and innovative, effective, state-of-the-art care, it is the only hospital in the state equipped with a 24/7 on-site heart-care team committed to providing the highest standards of quality and care.
Business Standard
03-06-2025
- Health
- Business Standard
First-Ever Non-Surgical Transcatheter tricuspid Valve Replacement (TTVR-ViV ) Performed in Rajasthan
VMPL Jaipur (Rajasthan) [India], June 3: In a major medical breakthrough for Rajasthan, doctors at Eternal Hospital, Jaipur, have successfully replaced the tricuspid heart valve without open-heart surgery - a first-of-its-kind procedure in the state. Until now, only the aortic and mitral valves could be replaced using transcatheter techniques, but Eternal Hospital's expert heart team has now achieved this milestone with the help of Transcatheter Tricuspid Valve Replacement (TTVR). Dr. Prem Ratan Degawat, Director of Mitral & Tricuspid Valve Therapy, Associate Director TAVR & Senior Structural Heart Disease Expert at Eternal Hospital who performed this procedure said that "The complex procedure was performed on a 57-year-old male patient from Jayal, Nagaur, who had previously undergone two open-heart surgeries - first in 1985 and again in 2017. Due to severe bleeding complications during the second surgery, including heavy bleeding, a third open-heart surgery was considered extremely high-risk. The patient was facing serious health issues, including breathlessness, leg swelling, fluid accumulation in the abdomen, and fluid in the lungs for the past few months. Given his prior surgical history and deteriorating condition, open-heart surgery was ruled out. The heart team at Eternal decided to proceed with TTVR, a cutting-edge, minimally invasive technique in which the damaged tricuspid valve is replaced via catheter - without opening the chest. The entire procedure was completed in just 30 minutes. Fast recovery - Discharged in just three days Dr. Prashant Dwivedi, Director & Incharge for Structural Heart Disease program at Eternal Hospital, shared that the patient made a swift recovery and was discharged within three days of the procedure. He added, "Compared to traditional surgery, TTVR is much safer and allows for quicker recovery. In this case, the patient showed immediate improvement in symptoms." The successful procedure was carried out under the guidance of internationally renowned interventional cardiologist Dr. Samin K. Sharma and senior cardiac surgeon Dr. Ajeet Bana, Cardiac Anaesthetist Dr Navneet Mehta, Dr J S Makkar and Dr Hemant Chaturvedi. A new hope for high-risk patients Mrs. Manju Sharma, Co-Chairperson of Eternal Hospital, said: "Until now, patients who were considered inoperable had very limited options. With TTVR, we now have a new ray of hope for them." Dr. Pracheesh Prakash, CEO of Eternal Hospital, added:
Yahoo
02-06-2025
- Business
- Yahoo
Boston Scientific ends TAVR sales; J&J shares Monarch robot data
This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. Boston Scientific said Wednesday it plans to end worldwide sales of its transcatheter aortic valve replacement systems, citing regulatory hurdles. The company will discontinue its Acurate Neo2 and Acurate Prime TAVR systems, which are sold in Europe, and will not pursue Food and Drug Administration approval for the devices. Boston Scientific said in a regulatory filing that the decision followed recent discussions with regulators, adding that the products faced increased requirements to maintain approvals in global markets and to obtain approvals in new regions. The company had told investors the 'path to approval in the U.S. was unclear and the approval requirements in Europe would be even greater,' Needham analyst Mike Matson wrote in a research note Wednesday. The decision followed Boston Scientific missing its primary endpoint in a trial comparing its Acurate Neo2 device to other TAVR systems. The Acurate business brought in about $200 million in sales last year, Matson wrote. 'Given the product's mixed clinical track record and complicated path to US approval, we're not surprised by Boston's choice to discontinue the product and redirect its time, effort, and dollars elsewhere,' J.P. Morgan analyst Robbie Marcus wrote in a research note. Marcus views the decision as the right strategy for Boston Scientific, even if the company takes a hit in the short term. Johnson & Johnson shared results of a study that found the company's Monarch bronchoscopy robot was able to reach small, peripheral lung nodules in more than 98% of cases. The robotic platform was able to locate and biopsy the nodules with a safety rate comparable to non-robotic bronchoscopy techniques, the company said in a Wednesday announcement. The TARGET study was published in Chest Journal on April 26 and was sponsored by J&J subsidiary Auris Health. The single-arm trial enrolled 679 people in the U.S., Canada and Hong Kong. Auris first received FDA clearance for the Monarch robot in 2018. J&J acquired the company a year later for $3.4 billion in cash. A software update for the system, intended to improve accuracy in reaching suspicious nodules, was cleared in March. Medtronic said Tuesday that a technology it is developing for its pulse oximeters was accepted into the FDA's Safer Technologies Program. The program is intended to support expedited development, assessment and review of devices that are expected to improve the safety of currently available devices. Medtronic is developing a technology to integrate patient- and sensor-specific data into oxygen saturation calculations used by its Nellcor pulse oximeters. Pulse oximeters have faced recent scrutiny by the FDA after studies have shown the devices may be less accurate for people with darker skin pigmentation. The agency issued a draft guidance in January updating testing recommendations for the devices, but it has not yet finalized the guidance. Last year, Medtronic agreed to provide labels and brochures to California hospital customers about the potential for flawed readings as part of a settlement with Roots Community Health, which sued 13 companies that make or sell pulse oximeters over the risk of disparities in treatment. Recommended Reading Edwards gains expanded TAVR label for asymptomatic patients Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
